Israeli MOH Hides Study Showing Adverse Events Following mRNA Vaccine in Kids
The study, commissioned by the MOH, also indicates new adverse events not reported in Pfizer’s leaflet, and that some adverse events last more than a year. Despite being aware of these findings, the MOH is hiding them from the public and has recently authorized the booster dose for ages 5-11 and is preparing to approve the vaccine for infants.
The serious findings revealed :
- Adverse events are 2-4 times more common among ages 5-11! This is despite the fact that immunization rates at younger ages are 3-4 times lower than older children.
- New adverse events that were not reported in Pfizer’s leaflet were identified.
- Contrary to what has been claimed, various adverse events, including serious ones, are not short-lived and transient. Some last more than a year.
- A significant proportion of the adverse events did not disappear by the end of the study, so it is not possible to know how long they lasted.
- Recurrence/exacerbation of adverse events following another dose was identified
While Pfizer CEO Albert Bourla is hosted in Israel and is promoting his company’s COVID vaccine for infants ahead of the Israeli Ministry of Health’s expected approval for infants in the coming days, it turns out that the ministry is hiding very serious findings on the vaccine’s adverse events in children, especially concerning children aged 5-11. Although the findings of the study, which was commissioned by the ministry itself, were presented to the Epidemiology Division three weeks ago, and despite their seriousness, the MOH authorized last week a third dose (“booster”) for ages 5-11 and announced that it plans to approve the vaccine for infants as early as this week.
In an urgent letter sent on Monday (June 27, 2022) by the Professional Ethics Front to the State Comptroller of Israel, Dr. Matanyahu Engelman, it was revealed that the findings of a study conducted by Prof. Matti Berkowitz, director of the Clinical Pharmacology and Toxicology Unit at Assaf Harofeh Hospital (Shamir) were presented to the Department of Epidemiology in early June. The study, which was commissioned by the Ministry of Health, examined the adverse events of Pfizer’s COVID vaccine for about six months (From December 9, 2021, until the end of May 2022). The study was based on an analysis of reports recorded in the Nahlieli system (a system that constitutes the Israeli national vaccine database, including the management of the accompanying information, which includes reports of adverse events and safety demonstrations). The letter to the State Comptroller stated that “The findings have been brought to our attention, and they are serious and indicate a risk to children, and in particular to young children aged 5-11”.
Today (June 29, 2022), the association sent another letter to the State Comptroller, detailing the serious findings, accompanied by slides presented to the Epidemiology Division by the research team led by Prof. Berkowitz.
The findings show, among other things, that adverse events are 2-4 times more common among young children aged 5-11; that there are new adverse events that have not been reported in Pfizer’s COVID vaccine leaflet; that contrary to what has been claimed, various adverse events, including neurological effects and menstrual disorders, are not short-term events that pass within a few days, but in many cases, they last for months or even more than a year. Moreover, the study found that a significant proportion of the symptoms did not disappear by the end of the study, so it is not possible to know how long they lasted; and a considerable part of the cases even if the adverse event ceased, it recurred after the next dose.